

Guidelines on AFIB - Focused Update (TF26) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Atar Dan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : Antiarrhythmic drug development (2010) - Sanofi Aventis : Antiarrhythmic drugs (2010) - Merck Sharp & Dohme : Antiarrhythmic drugs (2010) - Sequel Pharmaceuticals : Antiarrhythmic treatment in Atrial Fibrillation (2010) - Bayer : anticoagulants (2010) - Boehringer-Ingelheim : Anticoagulants (2010) - BMS/Pfizer : anticoagulants (2010) - Pfizer : Cholesterol lowering (2010) - Novartis : neurohumoral inhibition / blood pressure lowering (2010) - Astra Zeneca : Platelet inhibition (2010) - BMS : Prevention of Reperfusion Injury in STEMI (2010) - Kai Pharmaceuticals : Prevention of Reperfusion Injury in STEMI (2010) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Servier : anti-anginal medication (2010) - Population Research Institute, McMaster, Hamilton, Canada : Antiarrhythmic Therapy (2010) - TIMI group : anticoagulants (2010) - Duke Research Unit : Heart Failure Therapy (2010) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - EU-FP-7 grant / Trophos, Marseille : Prevention of Reperfusion Injury in STEMI (Leader of Clinical Research Consortium) (2010) <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> - Pronova Bioscience : Omega-3 and Platelet Function (2010)
Camm John	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - National Institute for Health and Clinical Excellence : Acute Coronary Syndrome Guidelines (2010) - Boston Scientific : Advisor - all products (2010) - Medtronic : Advisor - loop recorders (2010)

Guidelines on AFIB - Focused Update (TF26) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Camm John	<ul style="list-style-type: none"> - AGA : Amplatzer Cardiac Plug (2010-2011) - Wiley Blackwell : Clinical Cardiology (2010) - Wiley Blackwell : Clinical Cardiology (2011) - Boehringer-Ingelheim : Dabigatran (2010) - Boehringer-Ingelheim : Dabigatran (2011) - BMS : DSMB (2010-2011) - Cameron Health : DSMB (2010-2011) - Biotronik : DSMB - Ablation (2010-2011) - Novartis : DSMB - several (2011) - Novartis : DSMB - several (2010) - Oxford University Press : Europace and ESC textbook (2010-2011) - GlaxoSmithKline : General Advice (2010-2011) - Servier : Multiple products (2010-2011) - Sanofi Aventis : Multiple products (2010-2011) - Johnson & Johnson : Oncological Products (2010-2011) - Menarini : Ranolazine (2010-2011) - Bayer : Rivaroxaban (2010) - Bayer : Rivaroxaban (2011) - Cameron Health : Speaker - s-ICS (2010) - Merck Sharp & Dohme : Vernakalant (2010-2011) D - Research funding (departmental or institutional). <ul style="list-style-type: none"> - Servier : Antiarrhythmic drug (2010) - BMS/Pfizer : Apixaban (2010) - Sanofi Aventis : Clopidogrel (2010) - Daiichi Sankyo : Edoxaban (2010)

Guidelines on AFIB - Focused Update (TF26) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Camm John	<ul style="list-style-type: none"> - Richmond Pharmacology : Many phase 1 NCEs (2010) - Servier : Antiarrhythmic drug (2011) - BMS/Pfizer : Apixaban (2011) - Sanofi Aventis : Clopidogrel (2011) - Daiichi Sankyo : Edoxaban (2011) - Richmond Pharmacology : Many phase 1 NCEs (2011)
De Caterina Raffaele	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Novartis : aliskiren (2011) - BMS/Pfizer : apixaban (2010-2011) - Duke University : apixaban - APPRAISE-2 National coordinator (2010) - Duke Clinical Research Institute : apixaban - APPRAISE-2 National Coordinator (2011) - Medicines Company : bivalirudin, cangrelor (2010) - Sanofi Aventis : clopidogrel (2010) - Boehringer-Ingelheim : dabigatran (2010-2011) - F. Hoffman La Roche Ltd : dalcetrapib (2010) - Roche : dalcetrapib (2011) - Elsevier : Editor-in-Chief, Vascular Pharmacology (2010-2011) - Daiichi Sankyo : edoxaban (2011) - Sigma Tau : omega-3 fatty acids (2010) - Novartis : participant in aliskiren trials (2010) - Eli Lilly : prasugrel (2010) - Daiichi Sankyo : prasugrel, edoxaban (2010) - Bayer : rivaroxaban (2010) - Bayer Schering Pharma : rivaroxaban (2011) - Astra Zeneca : ticagrelor (2010)

Guidelines on AFIB - Focused Update (TF26) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
De Caterina Raffaele	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Bristol Myers Squibb : ARISTOTLE-AVERROES-APPRAISE-2 trials (2010) - Spa - Società Prodotti Antibiotici : omega-3 fatty acids (2010) - Novartis : participation in aliskiren trials (2010) - Roche Pharma : Participation in dalcetrapib trials (2010) - Bayer : rivaroxaban - ROCKET-AF trial (2010) - Novartis : Aliskiren trials (2011) - Roche : dalcetrapib trials (2011) - Daiichi Sankyo : edoxaban - ENGAGE-AF trial (2011) - Boehringer-Ingelheim : RELY-ABLE trial (2011)
Hindricks Gerhard	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Biosense Webster : Catheter (2010) - Stereotaxis : Catheter ablation (2011) - Biosense Webster : Catheter Ablation (2011) - Medtronic : Pacemaker (2011) - St Jude Medical : Pacemaker, Catheter (2010) - Biotronik : Pacemaker, Catheter (2010) - St Jude Medical : Pacemaker, catheter ablation (2011) - Biotronik : Pacemaker, catheter ablation (2011) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Stereotaxis : Catheter (2010) - Biosense Webster : Catheter (2010) - Medtronic : Pacemaker (2010) - St Jude Medical : Pacemaker, Catheter (2010) - Biotronik : Pacemaker, Catheter (2010) - Stereotaxis : catheter ablation (2011)

Guidelines on AFIB - Focused Update (TF26) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Hindricks Gerhard	<ul style="list-style-type: none"> - Biosense Webster : catheter ablation (2011) - St Jude Medical : Pacemake, catheter ablation (2011) - Medtronic : Pacemaker (2011) - Biotronik : Pacemaker, catheter ablation (2011)
Hohnloser Stefan H	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - BMS : apixaban (2010-2011) - Pfizer : apixaban (2010-2011) - Boehringer-Ingelheim : dabigatran (2010-2011) - Sanofi Aventis : dronedarone (2010-2011) - Medtronic : ICD (2011) - St Jude Medical : ICD SM (2011) - St Jude Medical : pacemaker (2010) - Bayer : rivaroxaban (2010) - Bayer Healthcare : rivaroxaban (2011)
Kirchhof Paulus	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - EHRA : arrhythmia management (2010) - BMS : cardiovascular (2011) - Boehringer-Ingelheim : cardiovascular (2011) - Daiichi Sankyo : cardiovascular (2011) - Medtronic : cardiovascular (2011) - St Jude Medical : cardiovascular (2011) - Sanofi Aventis : cardiovascular (2011) - Meda pharma : cardiovascular (2011) - Merck Sharp & Dohme : cardiovascular (2011) - Otsuka Pharmaceuticals Development and Commercialization (consultancy) : cardiovascular (2011)

Guidelines on AFIB - Focused Update (TF26) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Kirchhof Paulus	<ul style="list-style-type: none"> - Boston Scientific : cardiovascular devices (2010) - Medtronic : cardiovascular devices (2010) - St Jude Medical : cardiovascular devices (2010) - Biotronik : cardiovascular devices (2010) - Cordis : cardiovascular devices (2010) - Astra Zeneca : cardiovascular drugs (2010) - Bayer : cardiovascular drugs (2010) - Boehringer-Ingelheim : cardiovascular drugs (2010) - Daiichi Sankyo : cardiovascular drugs (2010) - Sanofi Aventis : cardiovascular drugs (2010) - GlaxoSmithKline : cardiovascular drugs (2010) - BMS/Pfizer : cardiovascular drugs (2010) - Meda pharma : cardiovascular drugs (2010) - Abbott Vascular : cardiovascular drugs (2010) - Takeda Pharmaceuticals : cardiovascular drugs (2010) - Bristol Myers Squibb : cardiovascular drugs (2010) - 3M : cardiovascular drugs (2010) - Merck Sharp & Dohme : cardiovascular drugs (2010) - Oxford University Press : heart disease management (2010) - WebMD : heart disease management (2010) - Heart.org : management of heart disease (2010) D - Research funding (departmental or institutional). <ul style="list-style-type: none"> - European Union : atrial fibrillation (2010) - Fondation Leducq : atrial fibrillation (2010) - St Jude Medical : cardiovascular devices (2010)

Guidelines on AFIB - Focused Update (TF26) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Kirchhof Paulus	<ul style="list-style-type: none"> - OMRON Healthcare : cardiovascular devices (2010) - Sanofi Aventis : cardiovascular drugs (2010) - 3M / MEDA Pharma : cardiovascular drugs (2010) - Cardiovascular Therapeutics : cardiovascular drugs (2010) - Deutsche Forschungsgemeinschaft : heart disease (2010) - St Jude Medical : cardiovascular (2011) - Sanofi Aventis : cardiovascular (2011) - Meda pharma : cardiovascular (2011)
Lip Gregory Yh	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Biotronik : atrial fibrillation (2010-2011) - Portola Pharmaceuticals : atrial fibrillation (2010) - Merck Sharp & Dohme : atrial fibrillation (2010) - BMS : atrial fibrillation, thrombosis (2010-2011) - Boehringer-Ingelheim : atrial fibrillation, thrombosis (2010-2011) - Pfizer : atrial fibrillation, thrombosis (2010-2011) - Bayer Healthcare : atrial fibrillation, thrombosis (2011) - Astellas : atrial fibrillation, thrombosis (2011) - Astellas : atrial fibrillation, thrombosis (2010) - Bayer Schering Pharma : atrial fibrillation, thrombosis (2010) - Daiichi Sankyo : atrial fibrillation, thrombosis [sums from each] (2010) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : atrial fibrillation, thrombosis (2010) - Bayer Schering Pharma : atrial fibrillation, thrombosis (2010) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Bayer Healthcare : atrial fibrillation, thrombosis (2010) - Bayer : atrial fibrillation, thrombosis (2011)

Guidelines on AFIB - Focused Update (TF26) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Savelieva Irene	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Sanofi Aventis : Antiarrhythmics (2010) - Menarini : Antiarrhythmics (2011) - Merck Sharp & Dohme : Antiarrhythmics (2011) - Boehringer-Ingelheim : Anticoagulants (2010-2011) - Daiichi Sankyo : Anticoagulants (2010-2011) - Bristol Myers Squibb : Anticoagulants (2010-2011) - Bayer AG : Anticoagulants (2011) - Astra Zeneca : Antiplatelets (2010) - Takeda Pharmaceuticals : Stroke (2010) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : Anticoagulants (2010) - Bristol Myers Squibb : Anticoagulants (2010) - Menarini : Anriarrhythmics (2011) - Daiichi Sankyo : Anticoagulants (2011) - Bristol Myers Squibb : Anticoagulants (2011)

This table represents the relevant relationships of the above experts with Industries and other entities that were reported to us at the time of publication of the Guidelines.

Guidelines on AFIB (focused update) (TF26) - Document Reviewers

Expert	Type of Relationship with Industry
Al-Attar Nawwar	None
Alfieri Ottavio	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Valtech : Mitral products (2011) - Edwards Lifesciences : Prosthetic rings (2011) - Symetis SA : Transapical aortic prosthesis (2011)
Angelini Annalisa	None
Blomstrom-Lundqvist Carina	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Sanofi Aventis : AF (2011) B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Biotronik : Arrhythmia (2011) - Medtronic : ICD, AF (2011) D - Research funding (departmental or institutional). - Medtronic : AF (2011) - Atricure : AF (2011) - Biotronik : Arrhythmias (2011)
Colonna Paolo	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Bracco Imaging : Contrast Echocardiography (2011)
De Sutter Johan	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : lipids (2011) - Pfizer : lipids (2011)
Ernst Sabine	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Medtronic : Catheter ablation (2011) - St Jude Medical : Catheter ablation (2011) - Biosense Webster : Catheter ablation (2011) - Stereotaxis : Remote navigation (2011) B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - St Jude Medical : Catheter ablation (2011) - Biosense Webster : Catheter ablation (2011)

Guidelines on AFIB (focused update) (TF26) - Document Reviewers

Expert	Type of Relationship with Industry
Ernst Sabine	D - Research funding (departmental or institutional). - Biosense Webster : 3D mapping (2011) - St Jude Medical : Catheter ablation (2011)
Goette Andreas	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boehringer-Ingelheim : Dabigatran (2011) - Daiichi Sankyo : Olmesartan (2011) - Bayer Healthcare : Rivaroxaban (2011) - Merck Sharp & Dohme : Vernakalant (2011)
Gorenek Bulent	None
Hatala Robert	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Abbott : drugs (2011) - Bayer : drugs (2011) - Boehringer-Ingelheim : drugs (2011) - Pfizer : drugs (2011) - Servier : drugs (2011) - Merck Sharp & Dohme : drugs (2011) B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Medtronic : CRM (2011) - St Jude Medical : CRM (2011) - Biotronik : CRM (2011) D - Research funding (departmental or institutional). - Medtronic : CRM (2011)
Heidbuchel Hein	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Biosense Webster : ablation (2011) - Sanofi Aventis : AF, hypertension (2011) - Merck Sharp & Dohme : anti-arrhythmic (2011) - Pfizer : anticoagulation (2011)

Guidelines on AFIB (focused update) (TF26) - Document Reviewers

Expert	Type of Relationship with Industry
Heibuchel Hein	<ul style="list-style-type: none"> - Bristol Myers Squibb : anticoagulation (2011) - Bayer : anticoagulation, anti-anginal (2011) - Boehringer-Ingelheim : anticoagulation, hypertension (2011) - Medtronic : devices (2011) - Biotronik : devices (2011) - Siemens Healthcare : imaging (2011) - Daiichi Sankyo : statins, oral anticoagulants (2011) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Biotronik : ablation (2011) - Forest Research : antiarrhythmics (2011) - Daiichi Sankyo : anticoagulation (2011) - Medtronic : devices (2011) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Boston Scientific : devices (unconditional grant) (2011) - Biotronik : devices (unconditional grant) (2011) - Medtronic : devices (unconditional grant) (2011) - Astra Zeneca : hypertension; ASHD; lipids (unconditional grant) (2011) - Siemens Healthcare : imaging (contract research) (2011)
Heldal Magnus	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Sanofi Aventis : Atrial fibrillation, Dronedarone (2011) - Merck Sharp & Dohme : Atrial fibrillation, Vernakalant (2011)
Kolh Philippe H	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Merck Sharp & Dohme : Antiarrhythmic agents (2011) - Astra Zeneca : Antiplatelet agents (2011) - Regado Biosciences : Antithrombotic agents (2011) - Abbott Vascular : Coronary stents (2011) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p>

Guidelines on AFIB (focused update) (TF26) - Document Reviewers

Expert	Type of Relationship with Industry
Kolh Philippe H	<ul style="list-style-type: none"> - Merck Sharp & Dohme : Antistaphylococcic vaccine (2011) D - Research funding (departmental or institutional). - Edwards Lifesciences : Cardiac valves (2011) - Medtronic : Cardiac valves (2011) - St Jude Medical : Cardiac valves (2011) - Boston Scientific : Coronary stents (2011) - Siemens Healthcare : Medical imaging (2011) - Johnson & Johnson : Thoracoscopic devices (2011)
Kristensen Steen Dalby	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : antitrombotics (2011) - Boehringer-Ingelheim : antitrombotics (2011) - Eli Lilly : antitrombotics (2011) - Pfizer : antitrombotics (2011) - Bayer Healthcare : antitrombotics (2011) - Medicines Company : antitrombotics (2011) - Bristol Myers Squibb : antitrombotics (2011) - Merck Sharp & Dohme : antitrombotics (2011)
Le Heuzey Jean-Yves	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Servier : antiarrhythmic (2011) - Sanofi Aventis : antiarrhythmic (2011) - Meda pharma : antiarrhythmic (2011) - Pierre-Fabre : antiarrhythmic (2011) - Merck Sharp & Dohme : antiarrhythmic (2011) - Bayer : anticoagulant (2011) - BMS : anticoagulant (2011) - Boehringer-Ingelheim : anticoagulant (2011)

Guidelines on AFIB (focused update) (TF26) - Document Reviewers

Expert	Type of Relationship with Industry
Le Heuzey Jean-Yves	<ul style="list-style-type: none"> - Daiichi Sankyo : anticoagulant (2011) - Medtronic : PM/ICD (2011) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Sanofi Aventis : antiarrhythmic (2011) - Daiichi Sankyo : anticoagulant (2011)
Mavrakis Iraklis	None
Mont Lluís	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - St Jude Medical : Atrial Fibrillation, Resynchronization Therapy. (2011) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Biosense Webster : Atrial Fibrillation (2011)
Perrone-Filardi Pasquale	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Roche Pharma : aleglitazar (2011) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Novartis : canakinumab (2011) - Daiichi Sankyo : edoxaban (2011) - schering plough : ezitimibe (2011) - Daiichi Sankyo : vorapaxar (2011) <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> - european community evinci study : non invasive imaging (2011)
Ponikowski Piotr	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Sanofi Aventis : antiarrhythmics (2011) - Merck Sharp & Dohme : antiarrhythmics (2011) - BMS : anticoagulant (2011) - Boehringer-Ingelheim : anticoagulant (2011) - Bayer Healthcare : anticoagulant (2011)
Prendergast Bernard David	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : Antiplatelet therapy (2011) - Medtronic : Stents, Transcatheter Valves (2011)

Guidelines on AFIB (focused update) (TF26) - Document Reviewers

Expert	Type of Relationship with Industry
Prendergast Bernard David	- Edwards Lifesciences : Transcatheter Valves (2011)
Rutten Frans Hendrik	None
Schotten Ulrich	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - MSD : Vernakalant (2011)
Van Gelder Isabelle C	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Bayer : atrial fibrillation (2011) - Boehringer-Ingelheim : atrial fibrillation (2011) - Merck Sharp & Dohme : atrial fibrillation (2011) - Medtronic : atrial fibrillation and heart failure (2011) - Biotronik : atrial fibrillation and heart failure (2011) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Medtronic : atrial fibrillation and heart failure research (2011) - Astra Zeneca : atrial fibrillation research (2011) - Bayer : atrial fibrillation research (2011) - Boehringer-Ingelheim : atrial fibrillation research (2011) - Boston Scientific : atrial fibrillation research (2011) - St Jude Medical : atrial fibrillation research (2011) - Biotronik : atrial fibrillation research (2011) - Sanofi Aventis : atrial fibrillation research (2011)
Vardas Panagiotis	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Bayer : Honoraria for participation in "ASP Alliance" and "SPAF Advisory Board". Speaker fees. (2011) - Boehringer-Ingelheim : Honorarium for participation in Advisory Board. Speaker fees (2011) - Menarini : Honorarium for participation in Ranolazine Advisory Board (2011) - Servier : Speaker and article-writing fees (2011) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Medtronic : Consultancy fee (2011) - Bristol Myers Squibb : Honorarium (2011)

Guidelines on AFIB (focused update) (TF26) - Document Reviewers

Expert	Type of Relationship with Industry
Vardas Panagiotis	<ul style="list-style-type: none"> - Bayer : Speaker fee (2011) - Boehringer-Ingelheim : Speaker fees and honoraria (2011) D - Research funding (departmental or institutional). <ul style="list-style-type: none"> - Amgen : ATOMIC AHF study (institutional) (2011) - Novartis : CANTOS study (institutional) (2011) - Medtronic : MORE CARE study (institutional) (2011) - Servier : SIGNIFY study (institutional) (2011)
Verheugt Freek	<ul style="list-style-type: none"> A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Bayer Healthcare : anticoagulants (2011)

This table represents the relevant relationships of the above experts with Industries and other entities that were reported to us at the time of publication of the Guidelines.

ESC Committee for Practice Guidelines 2010-2012

Expert	Type of Relationship with Industry
Baumgartner Helmut	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Actelion : Bosentan for PAH treatment in congenital heart disease (2010-2011) - AGA : Devices for catheter treatment of congenital heart defects (2010) - Edwards Lifesciences : transcatheter valve implantation (2011) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Edwards Lifesciences : transcatheter valve implantation (2010) - Actelion : Bosentan for PAH treatment in congenital heart disease (2011) - Edwards Lifesciences : transcatheter valve implantation (2011)
Bax Jeroen	<ul style="list-style-type: none"> - Heart.org : Education (2010) - Astra Zeneca : Farma (2010) - Servier : Farma (2010) - Philips : Imaging (2010) - GE Healthcare : Imaging (2010) - Lantheus Inc : Imaging (2010) - Boston Scientific : Pacing (2010) - Medtronic : Pacing (2010) - St Jude Medical : Pacing (2010) - Biotronik : Pacing (2010) - Impulse Dynamics : Pacing (2010) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Servier : Farma (2010) - Edwards Lifesciences : Heart Valves (2010) - GE Healthcare : Imaging (2010) - Lantheus Inc : Imaging (2010) - Boston Scientific : Pacing (2010) - Medtronic : Pacing (2010) - St Jude Medical : Pacing (2010) - Biotronik : Pacing (2010) - Servier : Farma (2011) - Edwards Lifesciences : Heart Valves (2011) - GE Healthcare : Imaging (2011) - Lantheus Inc : Imaging (2011) - Boston Scientific : Pacing (2011)

ESC Committee for Practice Guidelines 2010-2012

Expert	Type of Relationship with Industry
Bax Jeroen	<ul style="list-style-type: none"> - Medtronic : Pacing (2011) - St Jude Medical : Pacing (2011) - Biotronik : Pacing (2011)
Cecconi Claudio	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Servier : Pharmaceutical (2010-2011)
Deaton M Christi	<ul style="list-style-type: none"> - St Jude Medical : Cath lab - speaker X 1 (2010) - Daiichi Sankyo : consultant for patient adherence 2009-10 (2010) - Eli Lilly : consultant for patient adherence 2009-10 (2010) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Novo-Nordisk : medicines for diabetes (2010) - Novo-Nordisk : patients with heart failure and diabetes (2011)
Fagard Robert	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Servier : Honorarium for manuscript (2011) - Servier : Honorarium for manuscript in Medicographia (2010)
Funck-Brentano Christian	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Novartis CH : Adjudication Committee on an immunosuppressant (2011) - Lundbeck : Cardiac safety of an antidepressant (2011) - Pierre-Fabre : Cardiac Safety of non-cardiovascular products (2010-2011) - Servier : Cardiac safety of non-cardiovascular drugs under development or on the market. Design of phase I/II trials. (2010-2011) - Johnson & Johnson : Cardiac safety of non-cardiovascular drugs under development or on the market. Design of phase I/II trials. - MMV (CH) : Cardiac Safety of an antimalarial drug (2010-2011) - Santhera (CH) : Cardiac Safety of an antimalarial drug (2010-2011) - Sigma Tau : Cardiac Safety of an antimalarial drug (2010-2011) - TROPHOS : DSMB for an investigational drug in Amyotrophic Lateral Sclerosis – Cardiac safety (2010-2011) - CEPHALON : DSMB in an oncology phase IIb trial (2010-2011) - Jansen-Cilag : Proton-pump inhibitors and drug interactions, including Clopidogrel (2010-2011) - Intracellular Therapies USA : Psychotropic drug development (2011) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Jansen-Cilag : Proton-pump inhibitors and drug interactions with Clopidogrel (2010)
Hasdai David	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Sanofi Aventis : Enoxaparin (2010) - Boehringer-Ingelheim : Pradaxa (2011)

ESC Committee for Practice Guidelines 2010-2012

Expert	Type of Relationship with Industry
Hasdai David	<ul style="list-style-type: none"> - Bayer : Rivaroxiban (2011) - Astra Zeneca : Ticagrelor (2011) - Eli Lilly : Effient (2011)
Hoes Arno	<ul style="list-style-type: none"> - Zorg binnen Bereik : Member of project team of Zorg Binnen Bereik, a Dutch Achmea (health insurance company) and Philips - Boehringer-Ingelheim : Member Scientific Committee of Zorro; a research program sponsored by an unrestricted grant from D - Research funding (departmental or institutional). <ul style="list-style-type: none"> - Bayer Healthcare : unrestricted grant for diagnostic kits in suspected cardiovascular disease (2010) - Abbott Laboratories : unrestricted grant for diagnostic kits in suspected cardiovascular disease (2010) - Roche Pharma : unrestricted grant for diagnostic kits in suspected heart failure and acute coronary syndrome (2010) - I am the director of a large (around 500 employees) research and teaching institute within our University Medical Center. We perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. In addition, I chair a large (around 500 employees) research and teaching institute within our University Medical Center. We perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. In addition, some of my members of staff receive unrestricted grants for research projects from a number of companies. It is our explicit policy to work with several companies and not to focus on one or two industrial partners. I receive no personal payment from any industrial partner. (2011)
Kirchhof Paulus	<ul style="list-style-type: none"> A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none"> - BMS : cardiovascular (2011) - Boehringer-Ingelheim : cardiovascular (2011) - Daiichi Sankyo : cardiovascular (2011) - Medtronic : cardiovascular (2011) - St Jude Medical : cardiovascular (2011) - Sanofi Aventis : cardiovascular (2011) - Meda pharma : cardiovascular (2011) - Merck Sharp & Dohme : cardiovascular (2011) - Otsuka Pharmaceuticals Development and Commercialization (consultancy) : cardiovascular (2011) D - Research funding (departmental or institutional). <ul style="list-style-type: none"> - St Jude Medical : cardiovascular (2011) - Sanofi Aventis : cardiovascular (2011) - Meda pharma : cardiovascular (2011)
Knuuti Juhani	<ul style="list-style-type: none"> A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none"> - Lantheus Inc : Imaging tracers (2010) - Lantheus Inc : Perfusion imaging tracer development (2011)

ESC Committee for Practice Guidelines 2010-2012

Expert	Type of Relationship with Industry
Knuuti Juhani	<p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Bayer : Development of imaging agents (2010) - Novartis : Development of imaging agents (2010) - GE Healthcare : Development of imaging agents (2010) - Lantheus Inc : Development of imaging agents (2010) - Roche Pharma : Drugs for brain diseases (2010) - Astra Zeneca : Neurology (2011) - GE Healthcare : Neurology and molecular imaging (2011)
Kolh Philippe H	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Merck Sharp & Dohme : Antiarrhythmic agents (2010) - Merck Sharp & Dohme : Antiarrhythmic agents (2011) - Astra Zeneca : Antiplatelet agents (2010-2011) - Bristol Myers Squibb : Antiplatelet agents (2010) - Regado Biosciences : Antithrombotic agents (2010-2011) - Abbott : coronary stents (2010) - Abbott Vascular : Coronary stents (2011) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Merck Sharp & Dohme : Antistaphylococcic vaccine (2010) - Merck Sharp & Dohme : Antistaphylococcic vaccine (2011) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Edwards Lifesciences : Cardiac valves (2010) - Medtronic : Cardiac valves (2010) - St Jude Medical : Cardiac valves (2010) - Siemens Healthcare : Imaging (2010) - Johnson & Johnson : Thoracoscopic devices (2010) - Edwards Lifesciences : Cardiac valves (2011) - Medtronic : Cardiac valves (2011) - St Jude Medical : Cardiac valves (2011) - Boston Scientific : Coronary stents (2011) - Siemens Healthcare : Medical imaging (2011) - Johnson & Johnson : Thoracoscopic devices (2011)

ESC Committee for Practice Guidelines 2010-2012

Expert	Type of Relationship with Industry
McDonagh Theresa	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Vifor International : Ferrinject (2010-2011)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : Ivabridine (2010) - Servier : Ivabridine (2011)</p> <p>D - Research funding (departmental or institutional). - Biotronik : CRT (2010)</p>
Popescu Bogdan Alexandru	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - GE Healthcare : Imaging (2010-2011)</p>
Reiner Zeljko	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Bayer : anticoagulants (2011) - Bayer Healthcare : anticoagulants (2010) - Abbott : antilipemics (2010) - Astra Zeneca : antilipemics (2010-2011) - Pfizer : antilipemics (2010-2011) - Sanofi Aventis : antilipemics (2011) - Abbott Laboratories : antilipemics (2011) - Merck Sharp & Dohme : antilipemics (2010) - Merck Sharp & Dohme : antilipemics (2011)</p>
Sechtem Udo	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boehringer-Ingelheim : Anticoagulation (2010-2011) - Daiichi Sankyo : Antiplatelet therapy (2010) - Novartis : Drugs (2010-2011) - Pfizer : Drugs (2011) - Siemens Healthcare : Imaging (2010) - General Electric : Imaging (2010)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Novartis : Imaging devices (2010) - Johnson & Johnson : Stents (2010) - Novartis : Drugs (2011) - Johnson & Johnson : Stents (2011)</p>

ESC Committee for Practice Guidelines 2010-2012

Expert	Type of Relationship with Industry
Sirnes Per Anton	<p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Bayer : clinical studies atrial fibrillation investigator fee (ROCKET) (2010) - Merck Sharp & Dohme : investigator fee clinical studies hyperlipidemia, SCAD (THRIVE) (2010) - GlaxoSmithKline : investigator fee, clinical study , SCAD (2010) - Sanofi Aventis : investigator fee, clinical study (PALLAS) (2010) - Servier : investigator fee, clinical study, coronary artery disease (SIGNIFY) (2010) - Jansen-Cilag : investigator fee, clinical study, diabetes CVD (CANVAS) (2010) - Boehringer-Ingelheim : investigator fee, clinical study, AF (RELY. RELYABLE) (2010) - Merck Sharp & Dohme : investigator fee clinical studies hyperlipidemia, SCAD (THRIVE) (2011) - GlaxoSmithKline : investigator fee, clinical study , SCAD (2011) - Servier : investigator fee, clinical study, coronary artery disease (SIGNIFY) (2011) - Jansen-Cilag : investigator fee, clinical study, diabetes CVD (CANVAS) (2011)
Tendera Michal	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Bayer : Aspirin, Rivaroxaban (2011) - Amgen : Darbopietin (2011) - Servier : Ivabradine, Phase II investigational products (2011) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Servier : Ivabradine, Phase II investigational products (2011) - TIMI group : Rivaroxaban (2011)
Torbicki Adam	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : anticoagulation (2010) - Sanofi Aventis : anticoagulation (2010) - Pfizer : anticoagulation, pulmonary hypertension (2010) - United Therapeutics : Pulmonary arterial hypertension (2011) - GSK : pulmonary arterial hypertension - ambrisentan (2011) - Actelion : pulmonary arterial hypertension - macisentan, selexipag (2011) - Lilly : pulmonary arterial hypertension - tadalafil (2011) - AOP : Pulmonary arterial hypertension - treprostinil (2011) - Bayer Healthcare : pulmonary arterial hypertension - iloprost, riociguat (2011) - Actelion : pulmonary hypertension (2010) - Lilly : pulmonary hypertension (2010) - Bayer Healthcare : pulmonary hypertension, anticoagulation (2010) - Bristol Myers Squibb : thromboembolic disease - Apixaban (2011)

ESC Committee for Practice Guidelines 2010-2012

Expert	Type of Relationship with Industry
Torbicki Adam	<ul style="list-style-type: none"> - Bayer Healthcare : Pulmonary hypertension (2011) - Sanofi Aventis : Thromboembolic disease (2011)
Vahanian Alec	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Abbott : valve disease (2011) - Valtech : valve disease (2011) - Medtronic Foundation : valve disease (2011) - saint Jude medical : valve disease (2011) - Edwards Life sciences : valve disease (2011) - Abbott : Valve prostheses (2010) - Boehringer-Ingelheim : Valve prostheses (2010) - Edwards Lifesciences : Valve prostheses (2010) - Medtronic : Valve prostheses (2010) - Valtech : Valve prostheses (2010) - Siemens Healthcare : Valve prostheses (2010)
Windecker Stephan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : Antiplatelet drug (2010-2011) - Eli Lilly : Antiplatelet drug (2010-2011) - Abbott : Stent (2010-2011) - Biosensors : Stent (2010-2011) - Boston Scientific : Stent (2010-2011) - Medtronic : Stent (2010-2011) - Biotronik : Stent (2010-2011) - Cordis : Stent (2010-2011) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Abbott : Stent (2010) - Biosensors : Stent (2010) - Medtronic : Stent (2010) - Cordis : Stent (2010) - St Jude Medical : OCT (2011) - Abbott : Stent (2011) - Biosensors : Stent (2011) - Medtronic : Stent (2011) - Biotronik : Stent (2011)

ESC Committee for Practice Guidelines 2010-2012

Expert	Type of Relationship with Industry
Windecker Stephan	- Cordis : Stent (2011)

This table represents the relevant relationships of the above experts with Industries and other entities that were reported to us at the time of publication of the Guidelines.